GlassScriptPhysician profile
July Adams
NPI 1457723207
$5,627.13
in general payments reported to CMS, 2019-2025
38 companies · $63.50 in 2025
The $63.50 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,807 · 2022: $1,082 · 2023: $1,451 · 2024: $1,225 · 2025: $63.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.69 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.90 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $821.67 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.06 | 2021-2024 | Jardiance |
| Pfizer INC. | $362.06 | 2021-2024 | |
| Astellas Pharma US INC | $344.95 | 2021-2024 | Veozah, Myrbetriq |
| Amgen INC. | $272.63 | 2021-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $219.06 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $210.56 | 2021-2024 | |
| Lilly USA, LLC | $166.77 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $155.30 | 2022-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $147.52 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $141.71 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $105.42 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $105.21 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $100.18 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.81 | 2021-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $66.58 | 2021-2023 | Dificid |
| Sanofi-Aventis U.S. LLC | $57.47 | 2021-2022 | |
| Corium, LLC | $53.39 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $51.18 | 2021-2022 | |
| Genentech USA, INC. | $37.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $35.62 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $32.19 | 2024 | Auvelity |
| Lundbeck LLC | $22.33 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.01 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $18.72 | 2023 | |
| Sumitomo Pharma America, INC. | $18.10 | 2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $17.12 | 2021 | |
| Mylan Specialty L.P. | $16.57 | 2024 | Yupelri |
| Harmony Biosciences LLC | $16.49 | 2022 | |
| Si-Bone, INC. | $16.20 | 2021 | |
| Exact Sciences Corporation | $15.34 | 2024 | Cologuard Collection Kit |
| Tris Pharma INC | $14.76 | 2022 | |
| Horizon Therapeutics Plc | $14.49 | 2022 | |
| Ibsa Pharma INC. | $14.20 | 2022 | |
| Sanofi Pasteur INC. | $13.11 | 2021 | |
| Eisai INC. | $12.98 | 2021 | |
| Ucb, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw July Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.